Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05309421 | A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma | PHASE2 | ACTIVE NOT_RECRUITING | 17 | — | — | Sep 19, 2022 | Mar 30, 2026 | Sep 22, 2025 | 4 | Australia, Italy |
Composite of a BOR of complete response (CR) or PR for patients with SD at the time of first EVX-01 administration and a BOR of CR for patients with PR at the time of first EVX-01 administration, within 2 years of treatment with pembrolizumab, as per RECIST 1.1 criteria
| Arm | Type | Description |
|---|---|---|
| EVX-01 in combination with pembrolizumab | EXPERIMENTAL | EVX-01 is administered im. Pembrolizumab is administered according to label |
| Name | Type | Description |
|---|---|---|
| EVX-01 | DRUG | Investigational drug given in combination with standard of care |
| Pembrolizumab 25 MG/ML | DRUG | Standard of care |
Inclusion Criteria: * Be at least 18 years of age on day of signing informed consent. * Histologically confirmed, and not amenable to local therapy, metastatic or unresectable melanoma Stage III or Stage IV, as per AJCC 8th ed. staging system. 1. Patient may not have a diagnosis of uveal or ocul...